Psoriasis News

In this Healio video exclusive, Joel M. Gelfand, MD, MSCE, discusses the connection between psoriasis and cardiovascular outcomes.

CLEVELAND — With myriad treatment options now available for psoriasis vulgaris, recent research is focusing on reaching higher goals, Anthony P. Fernandez, MD, PhD, said at the Medical Dermatology Therapy Update III meeting.

A new antibody injection for the treatment of moderate to severe plaque psoriasis met all primary and key secondary endpoints in a phase 3 Chinese study, Innovent Biologics announced in a release.

Low stress resilience in men may be linked to an increased risk for developing psoriasis or psoriatic arthritis, according to a study.

Zai Lab Limited has dosed the first patient in a phase 2 trial of its topical chronic plaque psoriasis treatment candidate, the company announced in a press release.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

Bristol Myers Squibb announced results from its long-term extension trial of Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

Boehringer Ingelheim has partnered with Quallent Pharmaceuticals to expand access to its Humira biosimilar citrate-free adalimumab-adbm in the United States, according to a company press release.

Interleukin-17 and IL-23 inhibitors do not increase the risk for tuberculosis reactivation among patients with psoriatic disease who have a latent tuberculosis infection, according to a retrospective study.

SB17 was clinically biosimilar to ustekinumab for the treatment of moderate to severe psoriasis, according to a study.